🇺🇸 FDA
Pipeline program

CF101

CF101-231GL

Phase 2 small_molecule completed

Quick answer

CF101 for Ocular Hypertension is a Phase 2 program (small_molecule) at Can-Fite BioPharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Can-Fite BioPharma
Indication
Ocular Hypertension
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials